Search Results
Nov 10, 2025, 14:40 ET INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) and Encourages Investors with Substantial Losses to Contact the Firm
Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.
More news about: Edelson Lechtzin LLP
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. ("Arcturus" or the "Company") (NASDAQ: ARCT). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Sep 15, 2025, 08:30 ET Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is reporting positive phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate. ARCT-810 is designed to replace the OTC enzyme and restore
More news about: NetworkNewsWire